Tryptamine Therapeutics's quarterly market cap
declined
from Dec. 2022 (A$9.43 Mil) to Jun. 2023 (A$3.52 Mil) but then
increased
from Jun. 2023 (A$3.52 Mil) to Dec. 2023 (A$4.83 Mil).
Tryptamine Therapeutics's annual market cap
declined
from Jun. 2021 (A$87.97 Mil) to Jun. 2022 (A$20.44 Mil) and
declined
from Jun. 2022 (A$20.44 Mil) to Jun. 2023 (A$3.52 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Tryptamine Therapeutics's Enterprise Value for Today is A$4.72 Mil.
Tryptamine Therapeutics Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tryptamine Therapeutics's Market Cap
For the Biotechnology subindustry, Tryptamine Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tryptamine Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Tryptamine Therapeutics's Market Cap falls into.
Tryptamine Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Tryptamine Therapeutics's Market Cap for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tryptamine Therapeutics (ASX:TYP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Tryptamine Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Tryptamine Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Tryptamine Therapeutics (ASX:TYP) Business Description
Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:TYP has been successfully added to your 